1. Market Research
  2. > Frost & Sullivan’s 2014 Life Sciences Outlook

Frost & Sullivan’s 2014 Life Sciences Outlook

  • April 2014
  • -
  • Frost & Sullivan
  • -
  • 26 pages

In 2013, healthcare moved towards access, transparency, investments, and spending. In 2014, Frost & Sullivan anticipates new launches to occur across the life sciences spectrum, from preventive medicine to treating complex diseases. This market insight touches upon major events that occurred in 2013 and how 2014 is expected to shape up, including future investments, regulatory changes, and new launches. Key companies to watch are highlighted, and strategic recommendations are provided.

Executive Summary

The pharmaceutical/biotechnology industry is continuing to move away from the blockbuster
model approach and towards the treatment of orphan diseases and personalized medicine.

Continued growth in personalized medicine and companion diagnostics will move beyond
oncology and into areas such as virology, central nervous system, and cardiology.

While the number of new molecular entities (NMEs) continues to decline, the life sciences
industry has made great progress in treating complex conditions and providing greater ease
of use for patients (e.g., oral medicines for complex conditions such as hepatitis C and
multiple sclerosis).

The industry is seeing increasing speed and intensity of product competition in the areas of
generics and biosimilars, including the recent European launch of biosimilar monoclonal
antibodies (mAbs).

It is becoming the norm worldwide for payments and reimbursements to be tied to quality of

Pharmaceutical companies continue to move beyond the pill. Big pharma companies are
looking to adopt alternative business models beyond prescription treatments to support the
entire continuum of care such as disease prevention and patient monitoring.

Table Of Contents

Frost and Sullivan’s 2014 Life Sciences Outlook
Table of Contents

Executive Summary 3
2013—The Year That Was 5
2013—The Year That Saw Healthcare Moving Towards Access, Transparency, Investments, and Spending 6
Regulatory Transitions in 2013—Continuing Evolution 7
Accelerating Trends Make Their Mark Globally 8
What is to Come 9
Expected Future Investments 10
Shifting Strategies in the Global Marketplace 11
Life Sciences—2014 Outlook 12
New Launches Cross the Spectrum from Preventive to Complex 13
Life Science Companies To Watch in 2014 14
Frost and Sullivan Predictions for 2014 16
Legal Disclaimer 18
The Frost and Sullivan Story 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.